On this page
Back to topAgomAb Therapeutics AGMB
AgomAb Therapeutics listed on Nasdaq on 6 Feb 2026 and is not in the S&P 500. It is worth $192 million. 8 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 5 other officers are on file. At 30 Jun 2026, Eqt Fund Management S.a r.l. was its largest institutional holder, with 15.1% of the company.
- CEO
- Tim Jasper Knotnerus
- Listed
- 6 Feb 2026 on Nasdaq, IPO filings and terms
- Headquarters
- Antwerpen, Belgium
- Market cap
- $192M
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Board and leadership
Board and officers
Roles filed up to 30 Sep 2026
| Name | Title |
|---|---|
| Directors (8) | |
| Tim Jasper KnotnerusChief Executive OfficerLast filed 18 Mar 2026 | |
| Colin Michael BondDirectorLast filed 18 Mar 2026 | |
| David R. EpsteinDirectorLast filed 18 Mar 2026 | |
| Marino GarciaDirector | |
| Ohad HammerDirectorLast filed 18 Mar 2026 | |
| Angelika Martha JahreisDirectorLast filed 18 Mar 2026 | |
| Naimish PatelDirector | |
| Felice Isabel Verduyn-van WeegenDirectorLast filed 18 Mar 2026 | |
| Officers (5) | |
| Pierre Thadee Victor KemulaChief Financial OfficerLast filed 18 Mar 2026 | |
| Andrea Saez BorderiasChief Development OfficerLast filed 18 Mar 2026 | |
| Paul Henryk van der HorstChief Business OfficerLast filed 18 Mar 2026 | |
| Ellen LefeverGeneral CounselLast filed 18 Mar 2026 | |
| Philippe Constantin WieselChief Medical OfficerLast filed 18 Mar 2026 | |
Owners and trading
Largest institutional holders
Each fund group's share of AgomAb Therapeutics. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers made no open-market sales and bought $619,999 in 10 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 17 Nov 2026Buy | David R. EpsteinDirector | $28K |
| 13 Nov 2026Buy | David R. EpsteinDirector | $89K |
| 5 Nov 2026Buy | David R. EpsteinDirector | $104K |
| 21 Oct 2026Buy | David R. EpsteinDirector | $89K |
| 8 Oct 2026Buy | David R. EpsteinDirector | $45K |
| 6 Oct 2026Buy | Pierre Thadee Victor KemulaChief Financial Officer | $86K |
| 6 Oct 2026Buy | David R. EpsteinDirector | $44K |
| 6 Oct 2026Buy | Tim Jasper KnotnerusChief Executive Officer | $44K |
| 5 Oct 2026Buy | Tim Jasper KnotnerusChief Executive Officer | $51K |
| 5 Oct 2026Buy | David R. EpsteinDirector | $43K |
Not on file: no weekly market cap history, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months, no quarterly results in its SEC XBRL filings and no director or officer changes, WARN notices or large insider sales in the last two years.